Immunology-oncology ELISA kits sales will rise through 2036, driven by direct kits at 41% of the product segment in 2026. The market was valued at USD 10.80 billion in 2025 and is expected to be worth USD 15.94 billion by 2036, creating an incremental opportunity of USD 4.75 billion.